Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Eiger BioPharmaceuticals to host conference call » 08:08
11/23/20
11/23
08:08
11/23/20
08:08
EIGR

Eiger BioPharmaceuticals

$10.05 /

-0.34 (-3.27%)

Management discusses the…

Management discusses the FDA approval of Zokinvy (Lonafarnib), the first treatment for Hutchinson-Gilford Progeria Syndrome and processing deficient progeroid laminopathies on a conference call to be held on November 23 at 8:30 am. Webcast Link

ShowHide Related Items >><<
EIGR Eiger BioPharmaceuticals
$10.05 /

-0.34 (-3.27%)

EIGR Eiger BioPharmaceuticals
$10.05 /

-0.34 (-3.27%)

Hot Stocks
Eiger BioPharmaceuticals sells Priority Review Voucher for $95M » 08:05
11/23/20
11/23
08:05
11/23/20
08:05
EIGR

Eiger BioPharmaceuticals

$10.05 /

-0.34 (-3.27%)

Eiger BioPharmaceuticals…

Eiger BioPharmaceuticals announced that it has entered into a definitive agreement to sell its Priority Review Voucher for a lump sum payment of $95M. Eiger will retain fifty percent of the proceeds, or $47.5M, under the terms of the Collaboration and Supply Agreement with The Progeria Research Foundation. The PRV was granted in conjunction with the recent approval by the U.S. FDA of Zokinvy for treatment of Progeria and processing-deficient Progeroid Laminopathies. The transaction remains subject to customary closing conditions, including anti-trust review.

ShowHide Related Items >><<
EIGR Eiger BioPharmaceuticals
$10.05 /

-0.34 (-3.27%)

EIGR Eiger BioPharmaceuticals
$10.05 /

-0.34 (-3.27%)

Friday
Hot Stocks
Eiger BioPharmaceuticals trading resumes  18:16
11/20/20
11/20
18:16
11/20/20
18:16
EIGR

Eiger BioPharmaceuticals

$10.05 /

-0.34 (-3.27%)

 
ShowHide Related Items >><<
EIGR Eiger BioPharmaceuticals
$10.05 /

-0.34 (-3.27%)

EIGR Eiger BioPharmaceuticals
$10.05 /

-0.34 (-3.27%)

Hot Stocks
Eiger BioPharmaceuticals gets FDA approval of Zokinvy for HGPS treatment » 17:55
11/20/20
11/20
17:55
11/20/20
17:55
EIGR

Eiger BioPharmaceuticals

$10.05 /

-0.34 (-3.27%)

The company states:…

The company states: "Eiger BioPharmaceuticals announced that the FDA has approved Zokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome, or HGPS, and processing-deficient Progeroid Laminopathies, or PL. Progeria and Progeroid Laminopathies are separate and distinct ultra-rare, genetic, premature aging diseases that accelerate mortality in young patients. Disease manifestations include growth failure, loss of body fat and hair, aged-looking skin, stiffness of joints, hip dislocation, generalized atherosclerosis, cardiovascular disease and stroke. Zokinvy is a disease-modifying agent that has demonstrated a statistically significant survival benefit in children and young adults with Progeria. In patients with Progeria, Zokinvy reduced the incidence of mortality by 60% and increased average survival time by 2.5 years. The most commonly reported adverse reactions were gastrointestinal, and most were mild or moderate in severity. Many Progeria patients have received continuous Zokinvy therapy for more than 10 years."

ShowHide Related Items >><<
EIGR Eiger BioPharmaceuticals
$10.05 /

-0.34 (-3.27%)

EIGR Eiger BioPharmaceuticals
$10.05 /

-0.34 (-3.27%)

Hot Stocks
Eiger BioPharmaceuticals trading halted, news pending  16:53
11/20/20
11/20
16:53
11/20/20
16:53
EIGR

Eiger BioPharmaceuticals

$10.05 /

-0.34 (-3.27%)

 
ShowHide Related Items >><<
EIGR Eiger BioPharmaceuticals
$10.05 /

-0.34 (-3.27%)

EIGR Eiger BioPharmaceuticals
$10.05 /

-0.34 (-3.27%)

Conference/Events
FDA PDUFA Date for Eiger BioPharma Zokinvy (Lonafarnib) is November 20, 2020  09:13
11/20/20
11/20
09:13
11/20/20
09:13
EIGR

Eiger BioPharmaceuticals

$10.40 /

+0.12 (+1.17%)

 
ShowHide Related Items >><<
EIGR Eiger BioPharmaceuticals
$10.40 /

+0.12 (+1.17%)

EIGR Eiger BioPharmaceuticals
$10.40 /

+0.12 (+1.17%)

Over a week ago
Hot Stocks
Eiger announces oral presentation of Phase 2 LIFT results » 08:04
11/17/20
11/17
08:04
11/17/20
08:04
EIGR

Eiger BioPharmaceuticals

$10.95 /

+0.37 (+3.50%)

Eiger BioPharmaceuticals…

Eiger BioPharmaceuticals announced a late-breaker oral presentation of Phase 2 LIFT results at The Liver Meeting Digital Experience 2020. Week 48 end of study results were presented. Peginterferon lambda is a first-in-class type III interferon in development for hepatitis delta virus (HDV) infection, the most severe form of human viral hepatitis. The LIFT study was conducted within the National Institutes of Health (NIH) at the National Institute of Diabetes and Digestive and Kidney Diseases, or NIDDK, and was led by Christopher Koh, MD, Principal Investigator at the National Institute of Diabetes and Digestive and Kidney Diseases. LIFT is a Phase 2, open-label study of 26 adult patients with chronic HDV treated with Lambda 180 mcg once weekly in combination with Lonafarnib 50 mg boosted with ritonavir 100 mg twice daily for 24 weeks followed by 24 weeks of post-treatment follow-up.

ShowHide Related Items >><<
EIGR Eiger BioPharmaceuticals
$10.95 /

+0.37 (+3.50%)

EIGR Eiger BioPharmaceuticals
$10.95 /

+0.37 (+3.50%)

EIGR Eiger BioPharmaceuticals
$10.95 /

+0.37 (+3.50%)

Hot Stocks
Eiger BioPharmaceuticals presents case studies from completed Phase 2 LIMT » 16:11
11/16/20
11/16
16:11
11/16/20
16:11
EIGR

Eiger BioPharmaceuticals

$10.94 /

+0.36 (+3.40%)

Eiger BioPharmaceuticals…

Eiger BioPharmaceuticals announced a poster presentation of two case studies from the completed Phase 2 LIMT, or Lambda Interferon MonoTherapy in HDV, trial at The Liver Meeting Digital Experience 2020. Peginterferon lambda (Lambda) is a first-in-class type III interferon in development for hepatitis delta virus (HDV) infection, the most severe form of human viral hepatitis. The LIMT study enrolled a total of 33 patients with chronic HDV, randomized to monotherapy Lambda 180 undefined or Lambda 120 undefined, weekly subcutaneous injections for 48 weeks with 24 weeks of follow-up. Recently, administration of Lambda for 48 weeks was shown to induce a durable virologic response in 36% of patients with HDV and compensated liver disease. Impact of Lambda therapy on liver histology was not assessed in the LIMT study. Two patients who had liver biopsies prior to participation in the LIMT study, were re-biopsied 18 months after the last Lambda injection. Liver biopsies were staged according to the ISHAK scoring system, ranging from F0 (no fibrosis) to F6 (cirrhosis) and evaluated.

ShowHide Related Items >><<
EIGR Eiger BioPharmaceuticals
$10.94 /

+0.36 (+3.40%)

EIGR Eiger BioPharmaceuticals
$10.94 /

+0.36 (+3.40%)

EIGR Eiger BioPharmaceuticals
$10.94 /

+0.36 (+3.40%)

Earnings
Eiger BioPharmaceuticals reports Q3 EPS (52c), consensus (59c) » 17:42
11/05/20
11/05
17:42
11/05/20
17:42
EIGR

Eiger BioPharmaceuticals

$9.06 /

-0.2 (-2.16%)

Cash, cash equivalents,…

Cash, cash equivalents, and short-term investments as of September 30 totaled $125.3M.

ShowHide Related Items >><<
EIGR Eiger BioPharmaceuticals
$9.06 /

-0.2 (-2.16%)

EIGR Eiger BioPharmaceuticals
$9.06 /

-0.2 (-2.16%)

EIGR Eiger BioPharmaceuticals
$9.06 /

-0.2 (-2.16%)

Over a month ago
Hot Stocks
Eiger BioPharmaceuticals' Interferon Lambda shows COVID-19 load decline in trial » 08:05
10/15/20
10/15
08:05
10/15/20
08:05
EIGR

Eiger BioPharmaceuticals

$8.66 /

+0.06 (+0.70%)

Eiger BioPharmaceuticals…

Eiger BioPharmaceuticals announced results of the ILIAD Study - Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19 -, an investigator sponsored randomized trial of Peginterferon Lambda in outpatients with mild to moderate COVID-19 conducted at Toronto General Hospital, University Health Network in Toronto, Canada. The main efficacy outcomes were viral load decline and the proportion of individuals with a negative nasopharyngeal swab for SARS-CoV-2 at Day 7. A total of 60 patients were followed for 14 days. The SARS-CoV-2 RNA viral load decline from baseline was significantly greater in the Lambda group than in the placebo group from Day 5 onwards. After controlling for baseline viral load, those treated with Lambda were 4.1-fold more likely to clear by Day 7 than those in the placebo arm. For those with baseline viral load greater than 6 log copies/mL, the proportion negative at Day 7 in the Lambda group was 15 of 19 - 79% - compared to 6 of 16 - 38% - in the placebo group. This difference translated into a median time to clearance of 7 days with Lambda compared to 10 days in the placebo group. Across all patients, by Day 7, 24 of 30 patients - 80% - in the Lambda group were negative compared to 19 of 30 - 63% - in the placebo arm. Participants with low viral loads also had milder symptoms at baseline with symptoms improving over time in both groups. Lambda was well-tolerated with few adverse events, which included minimal elevations of transaminases which self-resolved.

ShowHide Related Items >><<
EIGR Eiger BioPharmaceuticals
$8.66 /

+0.06 (+0.70%)

EIGR Eiger BioPharmaceuticals
$8.66 /

+0.06 (+0.70%)

EIGR Eiger BioPharmaceuticals
$8.66 /

+0.06 (+0.70%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.